Oseltamivir acid
| Title | Journal |
|---|---|
| Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. | Drug metabolism and disposition: the biological fate of chemicals 20120801 |
| Species-dependent uptake of glycylsarcosine but not oseltamivir in Pichia pastoris expressing the rat, mouse, and human intestinal peptide transporter PEPT1. | Drug metabolism and disposition: the biological fate of chemicals 20120701 |
| Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus. | Bioorganic & medicinal chemistry 20120315 |
| Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir. | Bioorganic & medicinal chemistry 20110815 |
| Choroid plexus transport: gene deletion studies. | Fluids and barriers of the CNS 20110101 |
| Oseltamivir (tamiflu) induced depressive episode in a female adolescent. | Psychiatry investigation 20101201 |
| Oseltamivir (tamiflu) is a substrate of peptide transporter 1. | Drug metabolism and disposition: the biological fate of chemicals 20090801 |
| Aurintricarboxylic acid inhibits influenza virus neuraminidase. | Antiviral research 20090201 |
| Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). | Drug metabolism and disposition: the biological fate of chemicals 20090201 |
| Design, synthesis, inhibitory activity, and SAR studies of hydrophobic p-aminosalicylic acid derivatives as neuraminidase inhibitors. | Bioorganic & medicinal chemistry 20080401 |
| P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. | Drug metabolism and disposition: the biological fate of chemicals 20080201 |
| A QSAR study on influenza neuraminidase inhibitors. | Bioorganic & medicinal chemistry 20060215 |
| Investigation of neuraminidase-substrate recognition using molecular dynamics and free energy calculations. | Journal of medicinal chemistry 20031218 |
| In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. | Antiviral chemistry & chemotherapy 20030901 |
| Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series. | Biochemistry 20030128 |
| Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds. | Journal of virological methods 20021001 |
| In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. | Journal of virology 20020601 |
| Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. | Expert opinion on investigational drugs 20020601 |
| Structural studies of the resistance of influenza virus neuramindase to inhibitors. | Journal of medicinal chemistry 20020523 |
| In vitro and in vivo activities of anti-influenza virus compound T-705. | Antimicrobial agents and chemotherapy 20020401 |
| In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. | Antimicrobial agents and chemotherapy 20020401 |
| The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. | Drug metabolism and disposition: the biological fate of chemicals 20020101 |
| Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201. | Antiviral research 20011201 |
| Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. | Antimicrobial agents and chemotherapy 20011201 |
| Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. | Antimicrobial agents and chemotherapy 20010401 |
| In vitro and in vivo assay systems for study of influenza virus inhibitors. | Antiviral research 20001001 |
| BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. | Journal of medicinal chemistry 20000921 |
| Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. | Journal of chromatography. B, Biomedical sciences and applications 20000818 |
| Carbocyclic influenza neuraminidase inhibitors possessing a C3-cyclic amine side chain: synthesis and inhibitory activity. | Bioorganic & medicinal chemistry letters 20000605 |
| Synthesis and evaluation of 1,4,5,6-tetrahydropyridazine derivatives as influenza neuraminidase inhibitors. | Bioorganic & medicinal chemistry letters 19990705 |
| Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. | Antimicrobial agents and chemotherapy 19981201 |
| A new series of C3-aza carbocyclic influenza neuraminidase inhibitors: synthesis and inhibitory activity. | Bioorganic & medicinal chemistry letters 19981201 |
| Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. | Journal of medicinal chemistry 19980702 |
| GS4071 is a slow-binding inhibitor of influenza neuraminidase from both A and B strains. | Biochemical and biophysical research communications 19980317 |
| Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. | Antimicrobial agents and chemotherapy 19980301 |